Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/10230
Full metadata record
DC FieldValueLanguage
dc.coverage.spatialChemistryen_US
dc.date.accessioned2013-07-31T07:34:51Z-
dc.date.available2013-07-31T07:34:51Z-
dc.date.issued2013-07-31-
dc.identifier.urihttp://hdl.handle.net/10603/10230-
dc.description.abstractThe discovery of the crucial role of Peroxisome Proliferator Activated Receptors (PPARs) as regulators of lipid and glucose metabolism has raised interest in the development of synthetic ligands as potential tool for therapeutic intervention in type 2 diabetes mellitus (T2DM) and metabolic syndrome. newlineAn important class of compounds currently under focus in the same category is dual activators of Peroxisome Proliferator Activated Receptors (,). Each of these subtypes appears to be differentiated in a tissue-specific manner and to play a pivotal role in glucose and lipid homeostasis. Special efforts to design multiple activating molecules can be successfully made using computational methods. Knowledge of the 3D structure of all the targeted receptors is of an advantage. PPAR agonists enhance insulin action and promote glucose utilization in peripheral tissues. PPAR agonists improve insulin sensitivity associated with obesity and mediate their effects on lipid metabolism. Therefore PPAR/ dual activators provide superior profile toward the control of hyperglycemia and hypertriglyceridemia. So, we first aimed to work on the hypothesis that PPAR/ dual agonism must provide additive and positive synergistic pharmacology, and laid down certain objectives to meet and fulfill the issues facing the development of dual activating agonists: a balance between and activity. newlineThe fact that dual PPARand#945;/and#947; activators though highly potent agonists of PPARand#945; and and#947;; they lead to various undesirable adverse effects (cardiovascular, hepatic, carcinogenic etc.) came into picture in the due course of time during the research work. Partial agonism simultaneously to both the Receptors may provide solution to the problem of toxic adverse effects of dual activators. newlineWe accordingly planned to synthesize and validate computationally heterocyclyl linked acyclic analogs of oxazolidinediones i.e. and#945;-alkoxy propanoic acids, as was designed on the basis of 3D-QSAR studies, having almost all the structural features to acten_US
dc.format.extent635p.en_US
dc.languageEnglishen_US
dc.relationNo of References 562en_US
dc.rightsuniversityen_US
dc.titleHeterocyclyl linked a- alkoxy carboxylic acids as novel antidiabetic agents: design synthesis and computational validation studiesen_US
dc.title.alternative-en_US
dc.creator.researcherVijay Kumaren_US
dc.subject.keywordChemistryen_US
dc.subject.keywordantidiabetic agentsen_US
dc.description.noteReferences p.591-635en_US
dc.contributor.guideVerma, Raman Ken_US
dc.publisher.placePatialaen_US
dc.publisher.universityPunjabi Universityen_US
dc.publisher.institutionDepartment of Chemistryen_US
dc.date.registeredn.d.en_US
dc.date.completed2012en_US
dc.date.awarded2012en_US
dc.format.dimensions-en_US
dc.format.accompanyingmaterialNoneen_US
dc.type.degreePh.D.en_US
dc.source.inflibnetINFLIBNETen_US
Appears in Departments:Department of Chemistry

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File85.69 kBAdobe PDFView/Open
02_dedication.pdf36.6 kBAdobe PDFView/Open
03_certificate.pdf87.02 kBAdobe PDFView/Open
04_declaration.pdf99.22 kBAdobe PDFView/Open
05_acknowledgements.pdf19.43 kBAdobe PDFView/Open
06_contents.pdf147.42 kBAdobe PDFView/Open
07_chapter 1.pdf1.42 MBAdobe PDFView/Open
08_chapter 2.pdf2.22 MBAdobe PDFView/Open
09_chapter 3.pdf9.9 MBAdobe PDFView/Open
10_chapter 4.pdf10.16 MBAdobe PDFView/Open
11_chapter 5.pdf658.31 kBAdobe PDFView/Open
12_references.pdf857.61 kBAdobe PDFView/Open
13_abstract.pdf139.87 kBAdobe PDFView/Open


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: